ADHERIUM LIMITED — Board/Management Information 2016

Aug 3, 2016

==> picture [199 x 55] intentionally omitted <==

ANNOUNCEMENT

Adherium Builds Senior Leadership Team with New Chief Operating Officer and New Head of Corporate Development

Melbourne, Australia, 4 August 2016: Adherium has appointed its new Chief Operating Officer, Ross Bradding, and a new Head of Corporate Development, Julia Chambers.

Ross joins Adherium from First NZ Capital (FNZC). With his 25+ years of global experience with international Tier 1 banks, including Goldman Sachs, Credit Suisse First Boston, Industrial Bank of Japan, and FNZC, Ross brings exceptionally strong international financial services expertise to Adherium. After eleven years in London and two years in Sydney, Ross returned to New Zealand in 2003. From 2007 until recently, Ross was the Chief Operating Officer – Securities at FNZC, where he was responsible for enhancing the operating model of FNZC’s Securities business and managing the Auckland Wealth Management advisory team.

“Joining such a dynamic company as Adherium with its rapid global growth is an exciting challenge, and I very much look forward to working with the team to help shape the business for the opportunities ahead” said Bradding.

Julia joins Adherium from Callaghan Innovation, with more than 20 years’ experience in the global life science industry, working in sectors such as pharmaceuticals and biotechnology. Julia has significant commercial experience in the Bio-pharmaceutical sector; joining Genzyme in 2002, Julia ultimately became Senior Director of Commercial Assessment, focusing on the identification and acquisition of external innovation through licensing, partnerships and M&A. Prior to Genzyme, Julia spent six years in various sales and marketing roles with Eli Lilly UK. Upon coming to New Zealand in 2014 until recently, Julia was a Business Innovation Advisor with Callaghan Innovation.

“I’m delighted to be joining the Adherium team at what is an incredibly exciting time and look forward to making a significant contribution to the growth of the Company” Chambers said.

Sutherland, Group CEO of Adherium, said today: “It is great to have these pivotal roles filled by Ross and Julia. Their expertise and experience will substantially help the Company increase its scale rapidly.”

ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease. Adherium operates globally from bases in New Zealand, Australia, USA and UK.

Adherium is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organisations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

The Smartinhaler™ platform has so far been used in 63 projects (clinical, device validation or other) and has been referenced in 33 peer reviewed journal articles. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

www.adherium.com www.smartinhaler.com

Enquiries:
At Adherium:			Media enquiries:
Corporate AU/NZ	North America	Europe	AU/NZ Media	US Media
Rob Turnbull	James Hattersley	John Tarplee	Rudi Michelson	Erich Sandoval
Chief Financial Officer	SVP Business Development	SVP Business Development	Monsoon Communications	Lazar Partners
M: +64 21 887 628	M: +1 610 955 5886	M: +44 791 770 1846	D: +61 3 9620 3333	D: +1 213-908-6226
E: robt@adherium.com	E:jamesh@adherium.com	E:johnt@adherium.com	E: rudim@monsoon.com.au	E: esandoval@lazarpartners.com